Radiotherapy in the Era of Immunotherapy With a Focus on Non-Small-Cell Lung Cancer: Time to Revisit Ancient Dogmas?

由 Khalifa, Jonathan, Mazieres, Julien, Gomez-Roca, Carlos, Ayyoub, Maha, Moyal, Elizabeth Cohen-Jonathan
發表在 Front Oncol (2021)

Phase I dose-escalation study of F14512, a polyamine-vectorized topoisomerase II inhibitor, in patients with platinum-refractory or resistant ovarian cancer

由 Leary, Alexandra, Le Tourneau, Christophe, Varga, Andrea, Sablin, Marie-Paule, Gomez-Roca, Carlos, Guilbaud, Nicolas, Petain, Aurelie, Pavlyuk, Mariya, Delord, Jean-Pierre
發表在 Invest New Drugs (2018)

Sicca Syndrome Induced by Immune Checkpoint Inhibitor Therapy: Optimal Management Still Pending

由 Ortiz Brugués, Ariadna, Sibaud, Vincent, Herbault‐Barrés, Beatrice, Betrian, Sarah, Korakis, Iphigenie, De Bataille, Caroline, Gomez‐Roca, Carlos, Epstein, Joel, Vigarios, Emmanuelle
發表在 Oncologist (2019)

Phase I trial of afatinib and 3-weekly trastuzumab with optimal anti-diarrheal management in patients with HER2-positive metastatic cancer

由 Martin, Nicolas, Isambert, Nicolas, Gomez-Roca, Carlos, Goeldner, Rainer-Georg, Zanetta, Sylvie, Sadrolhefazi, Behbood, de Mont-Serrat, Hélène, Campone, Mario, Delord, Jean-Pierre
發表在 Cancer Chemother Pharmacol (2018)

Tumor Growth Rate (TGR) is an early indicator of anti-tumor drug activity in phase I clinical trials

由 Ferté, Charles, Fernandez, Marianna, Hollebecque, Antoine, Koscielny, Serge, Levy, Antonin, Massard, Christophe, Balheda, Rastislav, Bot, Brian, Gomez-Roca, Carlos, Dromain, Clarisse, Ammari, Samy, Soria, Jean-Charles
出版 2013

Clinical Response of Carcinomas Harboring the BRD4-NUT Oncoprotein to the Targeted Bromodomain Inhibitor OTX015/MK-8628

由 Stathis, Anastasios, Zucca, Emanuele, Bekradda, Mohamed, Gomez-Roca, Carlos, Delord, Jean-Pierre, de La Motte Rouge, Thibault, Uro-Coste, Emmanuelle, de Braud, Filippo, Pelosi, Giuseppe, French, Christopher A.
發表在 Cancer Discov (2016)

Phase I clinical study of RG7356, an anti-CD44 humanized antibody, in patients with acute myeloid leukemia

由 Vey, Norbert, Delaunay, Jacques, Martinelli, Giovanni, Fiedler, Walter, Raffoux, Emmanuel, Prebet, Thomas, Gomez-Roca, Carlos, Papayannidis, Cristina, Kebenko, Maxim, Paschka, Peter, Christen, Randolph, Guarin, Ernesto, Bröske, Ann-Marie, Baehner, Monika, Brewster, Michael, Walz, Antje-Christine, Michielin, Francesca, Runza, Valeria, Meresse, Valerie, Recher, Christian
發表在 Oncotarget (2016)

The Activity of Crizotinib in Chemo-Refractory MET-Amplified Esophageal and Gastric Adenocarcinomas: Results from the AcSé-Crizotinib Program

由 Aparicio, Thomas, Cozic, Nathalie, de la Fouchardière, Christelle, Meriaux, Emeline, Plaza, Jérome, Mineur, Laurent, Guimbaud, Rosine, Samalin, Emmanuelle, Mary, Florence, Lecomte, Thierry, Gomez-Roca, Carlos, Haineaux, Paul-Arthur, Gratet, Alain, Selves, Jannick, Menu, Yves, Colignon, Nikias, Johnson, Laetitia, Legrand, Frédéric, Vassal, Gilles
發表在 Target Oncol (2021)

Safety and antitumor activity of the anti–PD-1 antibody pembrolizumab in patients with advanced colorectal carcinoma

由 O’Neil, Bert H., Wallmark, John M., Lorente, David, Elez, Elena, Raimbourg, Judith, Gomez-Roca, Carlos, Ejadi, Samuel, Piha-Paul, Sarina A., Stein, Mark N., Abdul Razak, Albiruni R., Dotti, Katia, Santoro, Armando, Cohen, Roger B., Gould, Marlena, Saraf, Sanatan, Stein, Karen, Han, Sae-Won
發表在 PLoS One (2017)

From presentation to paper: Gender disparities in oncological research

由 Dijksterhuis, Willemieke P.M., Stroes, Charlotte I., Tan, Wan‐Ling, Ithimakin, Suthinee, Calles, Antonio, van Oijen, Martijn G.H., Verhoeven, Rob H.A., Barriuso, Jorge, Oosting, Sjoukje F., Ivankovic, Daniela Kolarevic, Furness, Andrew J.S., Bozovic‐Spasojevic, Ivana, Gomez‐Roca, Carlos, van Laarhoven, Hanneke W.M.
發表在 Int J Cancer (2019)

A Phase 1 dose-escalation study to evaluate safety, pharmacokinetics and pharmacodynamics of AsiDNA, a first-in-class DNA repair inhibitor, administered intravenously in patients w...

由 Le Tourneau, Christophe, Delord, Jean-Pierre, Kotecki, Nuria, Borcoman, Edith, Gomez-Roca, Carlos, Hescot, Ségolène, Jungels, Christiane, Vincent-Salomon, Anne, Cockenpot, Vincent, Eberst, Lauriane, Molé, Audrey, Jdey, Wael, Bono, Françoise, Trochon-Joseph, Véronique, Toussaint, Hélène, Zandanel, Christelle, Adamiec, Olga, de Beaumont, Olivier, Cassier, Philippe Alexandre
發表在 Br J Cancer (2020)

PD-1 blockade restores helper activity of tumor-infiltrating, exhausted PD-1(hi)CD39(+) CD4 T cells

由 Balança, Camille-Charlotte, Salvioni, Anna, Scarlata, Clara-Maria, Michelas, Marie, Martinez-Gomez, Carlos, Gomez-Roca, Carlos, Sarradin, Victor, Tosolini, Marie, Valle, Carine, Pont, Frédéric, Ferron, Gwénaël, Gladieff, Laurence, Vergez, Sébastien, Dupret-Bories, Agnès, Mery, Eliane, Rochaix, Philippe, Fournié, Jean-Jacques, Delord, Jean-Pierre, Devaud, Christel, Martinez, Alejandra, Ayyoub, Maha
發表在 JCI Insight (2021)

First-in-human phase I clinical trial of RG7356, an anti-CD44 humanized antibody, in patients with advanced, CD44-expressing solid tumors

由 Menke-van der Houven van Oordt, C. Willemien, Gomez-Roca, Carlos, van Herpen, Carla, Coveler, Andrew L., Mahalingam, Devalingam, Verheul, Henk M. W., van der Graaf, Winette T. A., Christen, Randolph, Rüttinger, Dominik, Weigand, Stefan, Cannarile, Michael A., Heil, Florian, Brewster, Michael, Walz, Antje-Christine, Nayak, Tapan K., Guarin, Ernesto, Meresse, Valerie, Le Tourneau, Christophe
發表在 Oncotarget (2016)

Phase Ib study of anti-CSF-1R antibody emactuzumab in combination with CD40 agonist selicrelumab in advanced solid tumor patients

由 Machiels, Jean-Pascal, Gomez-Roca, Carlos, Michot, Jean-Marie, Zamarin, Dmitriy, Mitchell, Tara, Catala, Gaetan, Eberst, Lauriane, Jacob, Wolfgang, Jegg, Anna-Maria, Cannarile, Michael A, Watson, Carl, Babitzki, Galina, Korski, Konstanty, Klaman, Irina, Teixeira, Priscila, Hoves, Sabine, Ries, Carola, Meneses-Lorente, Georgina, Michielin, Francesca, Christen, Randolph, Rüttinger, Dominik, Weisser, Martin, Delord, Jean-Pierre, Cassier, Philippe
發表在 J Immunother Cancer (2020)

Dose-painting multicenter phase III trial in newly diagnosed glioblastoma: the SPECTRO-GLIO trial comparing arm A standard radiochemotherapy to arm B radiochemotherapy with simulta...

由 Laprie, Anne, Ken, Soléakhéna, Filleron, Thomas, Lubrano, Vincent, Vieillevigne, Laure, Tensaouti, Fatima, Catalaa, Isabelle, Boetto, Sergio, Khalifa, Jonathan, Attal, Justine, Peyraga, Guillaume, Gomez-Roca, Carlos, Uro-Coste, Emmanuelle, Noel, Georges, Truc, Gilles, Sunyach, Marie-Pierre, Magné, Nicolas, Charissoux, Marie, Supiot, Stéphane, Bernier, Valérie, Mounier, Muriel, Poublanc, Muriel, Fabre, Amandine, Delord, Jean-Pierre, Cohen-Jonathan Moyal, Elizabeth
發表在 BMC Cancer (2019)

ACTR-30. UPDATED EFFICACY AND SAFETY OF DABRAFENIB PLUS TRAMETINIB IN PATIENTS WITH RECURRENT/REFRACTORY BRAF V600E–MUTATED HIGH-GRADE GLIOMA (HGG) AND LOW-GRADE GLIOMA (LGG)

由 Wen, Patrick, Stein, Alexander, van den Bent, Martin, De Greve, Jacques, Dietrich, Sascha, De Vos, Filip, von Bubnoff, Nikolas, van Linde, Myra, Lai, Albert, Prager, Gerald, Campone, Mario, Fasolo, Angelica, Lopez-Martin, Jose, Min Kim, Tae, Mason, Warren, Hofheinz, Ralf-Dieter, Blay, Jean-Yves, Cho, Daniel, Gazzah, Anas, Gomez-Roca, Carlos, Yachnin, Jeffrey, Boran, Aislyn, Burgess, Paul, Palanichamy, Ilan, Gasal, Eduard, Subbiah, Vivek
發表在 Neuro Oncol (2019)